News releases

Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.

To automatically receive future news releases, please go to the News subscription service page.

2014 - 2013 - 2012 - 2011 - [2010] - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003 - 2002

(click to view the full text)

December 20, 2010
Aeterna Zentaris Receives Agreement from FDA on Special Protocol Assessment for Solorel® (AEZS-130, Macimorelin) to Complete Registration Study for Diagnosis of Adult Growth Hormone Deficiency
December 14, 2010
Aeterna Zentaris Presents Comprehensive R&D Review and 2011 Strategic Outlook in New York City
December 7, 2010
Aeterna Zentaris To Hold R&D Review for Investors and Analysts in New York City on December 14, 2010
December 6, 2010
Aeterna Zentaris: Phase 2 Data Demonstrate Perifosine’s Promising Efficacy in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
December 2, 2010
Aeterna Zentaris Announces Poster Presentations of Perifosine at the Upcoming 52nd Annual Meeting of the American Society of Hematology
November 18, 2010
Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
November 17, 2010
Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
November 11, 2010
Aeterna Zentaris to Present at Upcoming Dundee Capital Markets Emerging Growth Conference in Toronto
November 10, 2010
Aeterna Zentaris to Present Phase 2 Results for AEZS-108 in Endometrial Cancer at Major Conference in Germany
November 9, 2010
Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
November 4, 2010
Aeterna Zentaris to Announce Third Quarter 2010 Financial and Operating Results on November 9, 2010
October 26, 2010
Aeterna Zentaris to Make Poster and Oral Presentations on Highly Selective Erk Inhibitor Compound, AEZS-131, at Major Cancer Conference in Boston
October 19, 2010
Aeterna Zentaris CEO to Chair Cancer Symposium Session at Upcoming BIT’s 8th Annual Congress of International Drug Discovery Science and Technology in Beijing
October 5, 2010
Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, SolorelTM) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
September 28, 2010
Aeterna Zentaris: Poster on Diagnostic Use of Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130 (Macimorelin, SolorelTM) to be Presented at Upcoming 5th International Congress of the GRS-IGF Society in New York
September 22, 2010
Aeterna Zentaris to Present at Upcoming Sachs 10th Annual Biotech Europe Investment Forum on September 29
September 7, 2010
Aeterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference on September 14
August 12, 2010
Aeterna Zentaris Reports Second Quarter 2010 Financial and Operating Results
August 5, 2010
Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
August 4, 2010
Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
August 3, 2010
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
July 14, 2010
Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
July 8, 2010
Aeterna Zentaris: Abstract on Diagnostic Use of Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130, to be Presented at Upcoming International Congress of Neuroendocrinology
June 29, 2010
Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
June 29, 2010
Aeterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Trial with Perifosine in Colorectal Cancer
June 28, 2010
Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
June 21, 2010
Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
June 21, 2010
Aeterna Zentaris Presents Positive Data at ENDO Meeting on AEZS-130, a Ghrelin Mimetic for Diagnostic and Therapeutic Use
June 16, 2010
Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
June 14, 2010
Aeterna Zentaris to Present Poster on Pharmacological and Toxicological Data on Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130, at Upcoming ENDO Annual Meeting
June 8, 2010
Aeterna Zentaris Reports Final Results of a Randomized, Double Blind, Placebo-Controlled Phase 2 Study of Perifosine in the Treatment of Advanced Metastatic Colorectal Cancer
June 7, 2010
Aeterna Zentaris Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma
June 7, 2010
Aeterna Zentaris Presents Positive Efficacy and Safety Data for AEZS-108 in Ovarian Cancer at ASCO Meeting
June 2, 2010
Aeterna Zentaris to Present at Upcoming Needham Annual Healthcare Conference on June 10, 2010
May 21, 2010
Aeterna Zentaris: Data on Lead Anticancer Compounds Perifosine and AEZS-108 to be Presented at Upcoming ASCO Annual Meeting
May 17, 2010
Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
May 17, 2010
Æterna Zentaris: Publication in the Journal of the National Cancer Institute Demonstrates Perifosine Single Agent Potential in Neuroblastoma Tumors
May 13, 2010
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
May 12, 2010
Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
May 11, 2010
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference on May 18, 2010
May 6, 2010
Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
May 6, 2010
Aeterna Zentaris to Announce First Quarter 2010 Financial and Operating Results and Hold Annual Shareholder Meeting on May 13, 2010
April 27, 2010
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
April 20, 2010
Aeterna Zentaris Presents a Poster on its Dual Inhibitors for PI3K and Erk, as well as an Oral Presentation Reporting Data on Selective Erk Inhibitors, at AACR Annual Meeting
April 20, 2010
Aeterna Zentaris: Poster Highlighting Preclinical Activity of Single-Agent Perifosine to be Presented at 2010 AACR Annual Meeting
April 20, 2010
Aeterna Zentaris Receives US$15 Million on Closing of Registered Direct Offering
April 16, 2010
Æterna Zentaris to Raise US$15 Million in Registered Direct Offering
April 15, 2010
Æterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Program with Perifosine in Multiple Myeloma
April 13, 2010
Æterna Zentaris to Present Data on Erk/PI3K Inhibitors at Upcoming AACR Annual Meeting
April 8, 2010
Æterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
April 5, 2010
Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for the Treatment of Refractory Advanced Colorectal Cancer
March 31, 2010
Æterna Zentaris to Present at BioFinance in Toronto on April 7
March 24, 2010
Æterna Zentaris Reports Fourth Quarter and Full-Year 2009 Financial and Operating Results
March 17, 2010
Æterna Zentaris to Announce Fourth Quarter Full Year 2009 Financial and Operating Results on March 24, 2010
March 1, 2010
Æterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for Perifosine for the Treatment of Multiple Myeloma from the Committee for Orphan Medicinal Products of the European Medicines Agency
February 23, 2010
Æterna Zentaris CEO to Take Part in Panel Discussion on Cancer Therapy at Upcoming RBC Capital Markets Healthcare Conference in New York on March 3
February 3, 2010
Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
January 29, 2010
Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom’s Macroglobulinemia
January 25, 2010
Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
January 22, 2010
Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
January 21, 2010
Æterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastrointestinal Cancers Symposium